Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new tool aims to demystify immunotherapy for advanced cancer patients

NCT ID NCT04670445

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and their knowledge, anxiety, and communication with their oncology team are measured. The goal is to see if this simple intervention helps people make more informed decisions about their treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Educational video and question prompt list
What this could lead to
If effective, this educational tool could improve how patients and caregivers understand immunotherapy, leading to more informed decisions and better communication with their oncology team.
What could go wrong
This is a pilot study focused on feasibility and knowledge change, not clinical outcomes. The intervention may not significantly improve understanding or reduce anxiety, and results may not generalize beyond this specific setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

199 people

The number who actually took part.

Started

Jan 2021

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All participants (Patients and Caregivers)-Table 1 * Age 18 or older * Ability to read and respond in English * Patient Inclusion Criteria (in addition to Table 1) * Receiving care in the MGH Cancer Center * Diagnosis of advanced (stage IV) melanoma or advanced, incurable lung cancer, including stage IV non-small cell lung cancer (NSCLC), unresectable stage III NSCLC, extensive-stage small cell lung cancer. * Plan to initiate immunotherapy with an ICI (pembrolizumab, nivolumab, ipilimumab, atezolizumab or combination), per clinician documentation in the electronic health record or study staff communication with clinician * Caregiver Inclusion Criteria (in addition to Table 1) * Identified as "a supportive person involved in their cancer care" by a patient enrolled in the study Exclusion criteria * Major psychiatric condition or comorbid illness that prohibits participation in the study * Cognitive impairment that prohibits provision of informed consent or participation in the study * Pregnant women * Prisoners

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma breast cancer breast neoplasm cervical carcinoma colorectal cancer colorectal neoplasm cutaneous neuroendocrine carcinoma endometrial cancer endometrium neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm head and neck squamous cell carcinoma hepatocellular carcinoma Liver Neoplasms lung cancer lung carcinoma malignant mesothelioma melanoma mesothelioma metastatic melanoma non-small cell lung carcinoma renal cell carcinoma skin basal cell carcinoma skin squamous cell carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck stage IVb bladder cancer Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced lung cancer Immune checkpoint inhibitors Immunotherapy Small cell lung cancer extensive stage Stage IV basal cell carcinoma Stage IV bladder cancer Stage IV breast cancer Stage IV cervical cancer Stage IV colorectal cancer Stage IV cutaneous squamous cell carcinoma Stage IV endometrial cancer Stage IV esophageal cancer Stage IV gastric cancer Stage IV head and neck squamous cell carcinoma Stage IV hepatocellular cancer Stage IV melanoma Stage IV merkel cell carcinoma Stage IV mesothelioma Stage IV non-small cell lung cancer Stage IV renal cell carcinoma Unresectable non-small cell lung carcinoma Unresectable stage III non-small cell lung cancer

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.